CAMBRIDGE - ProFound Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of
Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry Platform.
Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at
'With the new proteins we've uncovered to date through our proprietary ProFoundry Platform, we're continuing to redefine what we know about human biology to unlock a new world of first-in-class therapeutic possibilities,' said
'ProFound is illuminating the proteome in new ways, and I'm impressed with how the team has already discovered and implicated dozens of novel proteins as potential drugs and drug targets at an unprecedented rate,' said
About ProFound Therapeutics
ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company's ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded by Flagship Pioneering in 2020.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its
Contact:
Email: jzorbo@flagshippioneering.com
(C) 2023 Electronic News Publishing, source